Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 13, 2019
Daily News
December 13, 2019
- 2 Generic Makers List Fosrenol OD Copies after a Legal Win
December 13, 2019
- Keytruda on Track to Become a US$10 Billion Drug in 2019
December 13, 2019
- Lilly Japan Taps Robot to Prod Participation of Children in Clinical Trials
December 13, 2019
- Mulpleta Gets UK’s NICE OK for Thrombocytopenia: Shionogi
December 13, 2019
- Oncolys to Receive 500 Million Yen from Chugai in Telomelysin Milestone
December 13, 2019
- DS-8201 Achieves ORR of 60.9% in Global PII in HER2-Positive Breast Cancer: Daiichi Sankyo/AZ
December 13, 2019
- AnGes Acquiring 30%-Plus Stake in US Genome Editing Biopharma
December 13, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…